1EDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate In A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 
CONTINUATION: page_JLof pages. 
this occurrence. 
Although administration of immune lymphocytes can shrink tumors in some 
patients, many patients do not respond to the procedure and even those that 
exhibit shrinkage may show regrowth of the tumor after a short period of time 
(months ) . 
Gene-modified cells 
Recent scientific advances have made it possible to modify the genetic 
makeup of tumors in an effort to make them better able to be rejected by the 
immune system. The scientific advance is called "retroviral-mediated gene 
transfer" and allows us to insert a gene into some of your tumor cells, 
stimulating them to produce a hormone called IL-2. This hormone is naturally 
produced in the body in small amounts. The cells we give you may, however, 
produce too much IL-2 throughout the body. The introduction of this gene may 
or may not improve any possible anti-cancer effects of the tumor injection. 
We have inserted into your tumor, by a special laboratory technique, not only 
the human gene for IL-2 but a second gene taken from a bacterium that causes 
the tumor cells to be resistant to an antibiotic, neomycin. A gene is a part 
of a chromosome (hereditary material) that contains the information a cell 
needs to make proteins. 
The following procedure was used to insert these genes into your tumor. 
The tumor cells were attached to mouse virus genetic material that has the 
capacity to act as a carrier of foreign genes from one cell to another taking 
the two genes with it. These tumor cells are then grown in the laboratory in 
[132] 
Recombinant DNA Research, Volume 15 
N1H-K14-1 (1044) 
